Nurix Therapeutics NRIX Insider Ownership

Updated Oct 16, 2026

Over the past year, NRIX insiders sold $5.09 million of stock (266.05K shares) on the open market and bought none.

• Behind Nurix Therapeutics' open-market sales in the past 12 months were 4 insiders, and no insider bought.
• Christine Ring (Chief Legal Officer) was the top open-market seller of Nurix Therapeutics over the past 12 months, with $3.26 million sold (173.54K shares) and the latest sale on October 2, 2026.
• The newest open-market trade among Nurix Therapeutics insiders came on October 15, 2026, when Gwenn Hansen (Chief Scientific Officer) made a sale of 1.45K shares for $36,300.
• Away from the open market, NRIX insiders acquired 219.06K shares through option exercises and conversions over the last 12 months.
• Business Quant data shows Nurix Therapeutics insiders holding 177.25K shares in total in their latest Form 4 filings, or 0.16% of the 111.08Mn shares outstanding; that total is up 0.18% from 176.93K shares at the end of Q2 2026.
• NRIX's insiders hold all 177.25K shares directly, in their own names, with no indirect holdings.
• The insider holdings in Nurix Therapeutics belong to 4 insiders who have reported on Form 4 within the past two years.
• Nurix Therapeutics' three biggest insider holders are Gwenn Hansen (Chief Scientific Officer, 117.23K shares), Hans Van Houte (Chief Financial Officer, 40.17K shares) and Julia P. Gregory (Director, 10.75K shares), based on their latest Form 4 filings.
• Gwenn Hansen alone accounts for 66.14% of the shares held by Nurix Therapeutics insiders.
• In the last 12 months, 50 Form 4 filings with transactions in NRIX stock came from 12 insiders.
• This summary of Nurix Therapeutics insider activity covers Form 4 filings through October 15, 2026.